|
1) Collins AJ, Couser WG, Dirks JH, et al. World Kidney Day: an idea whose time has come. Kidney Int. 2006; 69: 781-2
|
|
|
|
2) Go AS, Chertow GM, Fan D, at al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296-305
|
|
|
|
|
|
3) Anavekar NS, McMurray JJ, Velazquez DJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351: 1285-95
|
|
|
|
|
|
4) Vanholder R, Massy Z, Argiles A, et al. Chronic kidney disease as a cause of cardiovascular morbidity and mortality. Nephrol Dial Transpl. 2005; 20: 1048-56
|
|
|
|
|
|
5) Kottgen A, Russel SD, Loehr LR, et al. Reduced kidney function as a risk factor for incident heart failure: The Atherosclerosis Risk in Communities(ARIC)study. J Am Soc Nephrol. 2007; 18: 1307-15
|
|
|
|
|
|
6) Hyre AD, Fox CS, Astor BC, et al. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment. Am J Kidney Dis. 2007; 49: 37-45
|
|
|
|
|
|
7) Hallan SI, Dahl K, Oien CM, et al. Screening strategies for chronic kidney disease in the general population: Follow-up of cross sectional health survery. BMJ. 2006; 333: 1047
|
|
|
|
|
|
8) Elsayed EF, Tighiouart H, Griffith J, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med. 2007; 167: 1130-6
|
|
|
|
|
|
9) Ninomiya T, Kiyohara Y, Kubo M, et al. Chronic kidney disease and cardiovascular disease in an general Japanese population: The Hisayama Study. Kidney Int. 2005; 68: 228-36
|
|
|
|
|
|
10) Kobayashi M, Hirawa N, Yatsu K, et al. Relationship between silent brain infarction and chronic kidney disease. Nephrol Dial Transplant. 2008. (in press)
|
|
|
|
|
|
11) 日本腎臓学会, 日本高血圧学会. CKD診療ガイド高血圧編, 第1版. 東京医学社; 2008
|
|
|
|
|
|
12) 日本腎臓学会. CKD診療ガイド, 第1版. 東京医学社; 2007
|
|
|
|
|
|
13) IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis. 2001; 37: S182-238
|
|
|
|
|
|
14) K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1-266
|
|
|
|
|
|
15) Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2005; 67: 2089-100
|
|
|
|
|
|
16) Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007; 298: 2038-47
|
|
|
|
|
|
17) 松尾清一. 日本とアジアにおける慢性腎臓病(CKD)対策の重要性. 日腎会誌. 2006; 48: 692-97
|
|
|
|
|
18) Foley RN, Parfrey PS, Sarnak MJ, et al. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32: S112-9
|
|
|
|
|
|
19) Hillege HL, Fidler V, Diercks GFH, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002; 106: 1777-82
|
|
|
|
|
|
20) de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation. 2004; 110: 921-7
|
|
|
|
|
|
21) de Zeeuw D, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004; 65: 2309-20
|
|
|
|
|
|
22) Shepherd J, Kastelein JJ, Bittner V, et al. Intensive lipid lowering with Atorvastatin in patients with coronary heart disease and chronic kidney disease: The TNT(Treating to New Targets)Study. J Am Coll Cardiol. 2008; 51: 1448-54
|
|
|
|
|
|
23) Shepherd J, Kastelein JJ, Bittner V, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: The Treating to New Targets(TNT) Study. Clin J Am Soc Nephrol. 2007; 2: 1131-9
|
|
|
|
|
|
24) Schrier RW. Role of diminished renal function in cardiovascular mortality. J Am Cell Cardiol. 2006; 47: 1-8
|
|
|
|
|
|
25) Stenvinkel P, Carrero JJ, Axelsson J, et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: How do new pieces fit into the uremic puzzle？ Clin J Am Soc Nephrol. 2008; 3: 505- 21
|
|
|
|
|
|
26) Yamagata K, Ishida K, Sairenchi T, et al. Risk factors for chronic kidney disease in a community-based population: a 10 year follow-up study. Kidney Int. 2007; 71: 159-66
|
|
|
|
|
|
27) Ueda S, et al. Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Nephrology (Carlton). 2007; 12; 582-90
|
|
|
|
|
|
28) Ravani P, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005; 16: 2449-55
|
|
|
|
|
|
29) 菱田 明. 日本腎臓学会としての慢性腎臓病(CKD)対策. 日腎会誌. 2006; 48: 688-91
|
|
|
|
|
|
30) 今井圓裕. CKDの概念. 治療. 2008; 90: 1386-91
|
|
|
|
|
|
31) Brosius III FC, Hostetter TH, Kelepouris E, et al. Detection of chronic kidney disease in patients with or at increased risk of cardiovascular disease. Circulation. 2006; 114: 1083-7
|
|
|
|
|
|
32) Vassalotti JA, Stevens LA, Levey AS. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007; 50: 169-80
|
|
|
|
|